Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703678 | 1.00 | INSR (0.42) | INSRALKSMN1; SMN2CA12CA1 | |
| SCHEMBL4699335 | 0.90 | KMT2A (0.39) | INSRALKSMN1; SMN2GAA | |
| SCHEMBL4699337 | 0.90 | KMT2A (0.39) | INSRALKSMN1; SMN2GAA | |
| SCHEMBL4700319 | 0.90 | INSR (0.38) | INSRALKSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4700317 | 0.90 | INSR (0.38) | INSRALKSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6193870 | 0.89 | POLB (0.39) | INSRALKSMN1; SMN2ALDH1A1 | |
| SCHEMBL6193876 | 0.89 | POLB (0.39) | INSRALKSMN1; SMN2ALDH1A1 | |
| SCHEMBL6195591 | 0.89 | INSR (0.37) | INSRALKSMN1; SMN2CA1CA2 | |
| SCHEMBL6195592 | 0.89 | INSR (0.37) | INSRALKSMN1; SMN2CA1CA2 | |
| SCHEMBL7108409 | 0.88 | ALDH1A1 (0.41) | INSRALKSMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335902-B1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1183236-B1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1335902-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | GERLACH UWE (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2003000244-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-6472413-B2 | FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002036565-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1183236-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| US-6350778-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-26 | — | — | US | disclosed |
| WO-2000071513-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, HCN3, CACNA1E | INSR 1814/4885ALK 1088/4885SMN1; SMN2 843/4885 |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | UTS2R, EIF2S1, TST | INSR 2359/4885ALK 937/4885SMN1; SMN2 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.